Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cohen

Showing results (981-990 of 1,023) with videos related to

Pageof 103
Sort By:
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
JAMA Oncology|November 16, 2023
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled TrialGlenn J Hanna, Alessandro Villa, Shuvro P Nandi, et al.
Science Translational Medicine|December 20, 2013
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerHiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, et al.
Ebiomedicine|September 30, 2022
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimensYunda Huang, Yuanyuan Zhang, Kelly E Seaton, et al.
Nature Cancer|January 2, 2026
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancerNadeem Riaz, Tyler J Alban, Robert I Haddad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2014
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypesMichaela K Keck, Zhixiang Zuo, Arun Khattri, et al.
Texas Dental Journal|July 12, 2012
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomasMichael P Rethman, William Carpenter, Ezra E W Cohen, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
Pageof 103

Showing results (981-990 of 1,023) with videos related to

Sort By:
Pageof 103
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.
JAMA Oncology|November 16, 2023
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled TrialGlenn J Hanna, Alessandro Villa, Shuvro P Nandi, et al.
Science Translational Medicine|December 20, 2013
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerHiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, et al.
Ebiomedicine|September 30, 2022
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimensYunda Huang, Yuanyuan Zhang, Kelly E Seaton, et al.
Nature Cancer|January 2, 2026
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancerNadeem Riaz, Tyler J Alban, Robert I Haddad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2014
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypesMichaela K Keck, Zhixiang Zuo, Arun Khattri, et al.
Texas Dental Journal|July 12, 2012
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomasMichael P Rethman, William Carpenter, Ezra E W Cohen, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
The Journal of Infectious Diseases|February 16, 2017
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy TrialHolly E Janes, Kristen W Cohen, Nicole Frahm, et al.
Pageof 103